New drugs in multiple myeloma – role of carfilzomib and pomalidomide

Carfilzomib (CFZ), an epoxyketone with specific chymotrypsin-like activity, is a second-generation proteasome inhibitor with significant activity in patients with relapsed and refractory multiple myeloma. On July 20, 2012, the US Food and Drug Administration approved CFZ to treat patients with multi...

Descripción completa

Detalles Bibliográficos
Autores principales: Jurczyszyn, Artur, Legieć, Wojciech, Helbig, Grzegorz, Hus, Marek, Kyrcz-Krzemień, Sławomira, Skotnicki, Aleksander B.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Termedia Publishing House 2014
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4037992/
https://www.ncbi.nlm.nih.gov/pubmed/24876816
http://dx.doi.org/10.5114/wo.2014.40175

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4037992/
https://www.ncbi.nlm.nih.gov/pubmed/24876816
http://dx.doi.org/10.5114/wo.2014.40175

Ejemplares similares